- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
TriLink to Open New GMP Facility Aimed at Early Phase Therapeutic Manufacturing
TriLink BioTechnologies announced their new 2,000 square foot diagnostic and pharmaceutical GMP production facility will be fully operational July 2014.
TriLink BioTechnologies announced their new 2,000 square foot diagnostic and pharmaceutical GMP production facility will be fully operational July 2014. TriLink’s new facility will feature validated ISO Class 7 and ISO Class 8 clean rooms, specifically designed to facilitate fast turnaround of IND-enabling tox and Phase 0/I GMP material. The company is a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA.
CEO Richard Hogrefe commented:
Our existing quality system, agile business model and extensive nucleic acid synthesis experience place us in a prime position to provide affordable IND and Phase I materials fast. We hope this new service provides an avenue for more nucleic acid based drugs to make it to the clinic.
Click here to view the full press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.